Genentech’s Alecensa shows promise in Phase III ALINA study for early-stage ALK-positive NSCLC

Genentech, a Roche Group member, has announced positive results from its Phase III ALINA study evaluating Alecensa (alectinib), setting a new standard for treating early-stage ... Read More